Data Highlights the Value of HeartCare and AlloSure Lung in Clinical Practice
Leading Experts Present Latest Advancements in Heart and Lung Transplantation During CareDx Symposia
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 43rd annual meeting & scientific sessions of the International Society for Heart and Lung Transplantation (ISHLT) with over 55 oral presentations and posters, and two symposia covering the latest advancements in surveillance and the clinical utility of these advancements in real-world applications for both heart and lung transplantation. The event will be held April 19-22 in Denver, Colorado.
“We are exceedingly proud to have a remarkable presence at this year’s ISHLT meeting with HeartCare data showing significant clinical benefits and compelling data supporting the advancement of AlloSure Lung into clinical practice,” said Reg Seeto, CEO and President of CareDx. “The significant body of evidence presented at ISHLT demonstrates the value of routinely incorporating CareDx’s non-invasive molecular solutions in heart and lung transplant clinical decision making.”
“HeartCare is a comprehensive molecular tool that we believe when used for surveillance provides insight into the risk of future significant clinical events compared to biopsies alone. Integrating this additional information will hopefully allow clinicians to further optimize and individualize post-transplant medical therapy,” said Dr. Jeffrey Teuteberg, MD, Cardiologist, and Professor of Cardiovascular Medicine at Stanford. “In fact, at Stanford Health Care we have moved away from routine surveillance with biopsies to multimodality molecular surveillance starting at one month as the standard for all patients who receive a cardiac transplant. In doing so, we have maintained excellent short and long-term outcomes and patients rarely require a biopsy.”
CareDx has assembled leading experts in the field who will review the use of HeartCare™ and AlloSure® Lung on clinical decision-making and in the management of challenging real-world scenarios.
- Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance, April 20, 11:30am, CDT. Moderated by Eugene DePasquale, MD, University of Southern California and Jeremy Kobulnik, MD, CareDx. Speakers include Albert J. Hicks III, MD, MPH, University of Maryland; Kiran Kaur Khush, MD, Stanford Health Care; and Nir Uriel, MD, MSc, Columbia University.
- Just Breathe - Facing Clinical Challenges in Lung Transplantation, April 21, 11:30am, CDT. Moderated by Deborah Jo Levine, MD, FCCP, FAST, Stanford University. Speakers include Hannah Mannem, MD, University of Virginia; Nirmal Sharma, MD, Brigham and Women’s Hospital; and Anil Trindade, MD, Vanderbilt University.
“I look forward to our scientific discussion during the HeartCare symposium which reviews ‘real-world’ clinical cases and how to use molecular tools to help manage complicated patient cases,” said Albert J. Hicks III, MD, Assistant Professor of Medicine, Medical Director of Heart Transplantation and Co-Director of Thoracic Transplant Quality at University of Maryland School of Medicine, and Advanced Heart Failure Cardiologist, University of Maryland Medical Center. “The expansive use of these molecular tools enables us to address a variety of real-world cases in ways that were much more difficult before.”
For a complete listing of abstracts, oral presentations and posters please follow this link.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s non-invasive testing services, HeartCare and AlloSure Lung, as well as its leading presence and participation in the 43rd annual meeting and scientific sessions of the International Society for Heart and Lung Transplantation (the “ISHLT Participation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of HeartCare, AlloSure Lung, or its ISHLT Participation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.